Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
Express Scripts
Deloitte
UBS
Federal Trade Commission
Cantor Fitzgerald
Fish and Richardson
Colorcon

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,192,615

« Back to Dashboard

Which drugs does patent 9,192,615 protect, and when does it expire?

Patent 9,192,615 protects SOLODYN and is included in one NDA.

This patent has thirteen patent family members in ten countries.
Summary for Patent: 9,192,615
Title:Method for the treatment of acne and certain dosage forms thereof
Abstract: An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/-0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/-0.2% hydroxypropoxylated.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Dallas, TX), Newhard; Steven B. (Scottsdale, AZ), Watt; David (Pickering, CA)
Assignee: Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:12/536,359
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,192,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-005 Jul 23, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,192,615

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,722,650 Extended-release minocycline dosage forms ➤ Sign Up
7,790,705 Minocycline oral dosage forms for the treatment of acne ➤ Sign Up
7,541,347 Minocycline oral dosage forms for the treatment of acne ➤ Sign Up
8,268,804 Minocycline oral dosage forms for the treatment of acne ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Medtronic
Fish and Richardson
Julphar
Cipla
Chinese Patent Office
Boehringer Ingelheim
Healthtrust
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.